Safety and feasibility of faecal microbiota transplantation for patients with Parkinson’s disease: a protocol for a self-controlled interventional donor-FMT pilot study

Autor: Maria Fiorella Contarino, Ed J Kuijper, Andrea E van der Meulen-de Jong, Josbert J Keller, Jacobus J van Hilten, Jelle J Goeman, Hein W Verspaget, Karuna EW Vendrik, Vlada O Chernova, Elisabeth M Terveer, Joffrey van Prehn, Eric KL Berssenbrugge, Jannie GE Henderickx, Martijn P Bauer, Romy D Zwittink

Publikováno v: BMJ Open, Vol 13, Iss 10 (2023)

Introduction Experimental studies suggest a role of gut microbiota in the pathophysiology of Parkinson’s disease (PD) via the gut–brain axis. The gut microbiota can also influence the metabolism of levodopa, which is the mainstay of treatment of

Externí odkaz: https://doaj.org/article/a1f26c1154924ebd886a4fa9d984ae94

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.

Autor: Mirthe E van der Valk, Marie-Josée J Mangen, Mirjam Severs, Mike van der Have, Gerard Dijkstra, Ad A van Bodegraven, Herma H Fidder, Dirk J de Jong, C Janneke van der Woude, Mariëlle J L Romberg-Camps, Cees H M Clemens, Jeroen M Jansen, Paul C van de Meeberg, Nofel Mahmmod, Andrea E van der Meulen-de Jong, Cyriel Y Ponsioen, Clemens Bolwerk, J Reinoud Vermeijden, Peter D Siersema, Max Leenders, Bas Oldenburg, COIN study group and the Dutch Initiative on Crohn and Colitis

Publikováno v: PLoS ONE, Vol 11, Iss 4, p e0142481 (2016)

With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related cos

Externí odkaz: https://doaj.org/article/a65838c5657347abb0fa1aa8abe71eed

Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer.

Autor: Christopher P E Lange, Mihaela Campan, Toshinori Hinoue, Roderick F Schmitz, Andrea E van der Meulen-de Jong, Hilde Slingerland, Peter J M J Kok, Cornelis M van Dijk, Daniel J Weisenberger, Hui Shen, Robertus A E M Tollenaar, Peter W Laird

Publikováno v: PLoS ONE, Vol 7, Iss 11, p e50266 (2012)

There is an increasing demand for accurate biomarkers for early non-invasive colorectal cancer detection. We employed a genome-scale marker discovery method to identify and verify candidate DNA methylation biomarkers for blood-based detection of colo

Externí odkaz: https://doaj.org/article/fada6eca2e264ae695fc74a84b5c1f63

Increased stromal PFKFB3-mediated glycolysis in inflammatory bowel disease contributes to intestinal inflammation

Autor: Zhou Zhou, Leonie G. Plug, Thiago A. Patente, Eveline S. M. de Jonge-Muller, Amir Abou Elmagd, Andrea E. van der Meulen-de Jong, Bart Everts, Marieke C. Barnhoorn, Lukas J. A. C. Hawinkels

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Inflammatory bowel disease (IBD) is a chronic relapsing inflammation of the intestinal tract with currently not well-understood pathogenesis. In addition to the involvement of immune cells, increasing studies show an important role for fibroblasts in

Externí odkaz: https://doaj.org/article/c20108b6498e4140b296ad82f27c4549

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry

Autor: Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Löwenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. van der Meulen‐de Jong, Marjolijn Duijvestein

Publikováno v: Alimentary Pharmacology & Therapeutics, 57, 1, pp. 117-126
Alimentary Pharmacology & Therapeutics, 57, 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell
Straatmijer, T, van Schaik, F D M, Bodelier, A G L, Visschedijk, M, de Vries, A C, Ponsioen, C Y, Pierik, M, van Bodegraven, A A, West, R L, de Boer, N K H, Srivastava, N, Romkens, T E H, Hoekstra, J, Oldenburg, B, Dijkstra, G, van der Woude, J C, Löwenberg, M, Mujagic, Z, Biemans, V B C, van der Meulen-de Jong, A E & Duijvestein, M 2023, ' Effectiveness and safety of tofacitinib for ulcerative colitis : two-year results of the ICC Registry ', Alimentary Pharmacology and Therapeutics, vol. 57, no. 1, pp. 117-126 . https://doi.org/10.1111/apt.17248
Alimentary Pharmacology & Therapeutics, 57(1), 117-126. Wiley
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. WILEY

Contains fulltext : 290620.pdf (Publisher’s version ) (Open Access) BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8627fcaccc449fd1031dddee12b17e7
https://doi.org/10.1111/apt.17248